Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VINNI JUNEJA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1639223522
CMS profile
28412
Location
ALEXANDRIA, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,912.10

178 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,725.00 2
Food and Beverage $3,804.59 172
Travel and Lodging $282.52 3
Education $99.99 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Seagen Inc. $4,867.88 11
PFIZER INC. $648.52 14
Janssen Biotech, Inc. $251.98 9
Celgene Corporation $190.98 9
Novartis Pharmaceuticals Corporation $185.51 7
Horizon Therapeutics plc $163.69 13
E.R. Squibb & Sons, L.L.C. $149.67 9
Amgen Inc. $147.34 8
GlaxoSmithKline, LLC. $133.29 5
BeiGene USA, Inc. $118.05 4
Mirati Therapeutics, Inc. $112.36 3
AstraZeneca Pharmaceuticals LP $96.05 4
GENZYME CORPORATION $95.62 4
Regeneron Healthcare Solutions, Inc. $95.35 4
Daiichi Sankyo Inc. $92.31 4
Eisai Inc. $84.52 4
Astellas Pharma US Inc $78.54 3
PharmaEssentia USA Corporation $77.67 3
Incyte Corporation $75.29 4
Merck Sharp & Dohme LLC $72.03 4
Kite Pharma, Inc. $70.04 3
AVEO Pharmaceuticals, Inc. $69.08 3
Genentech USA, Inc. $67.27 3
ABBVIE INC. $63.24 3
TerSera Therapeutics LLC $59.02 2
Alexion Pharmaceuticals, Inc. $58.68 2
SOBI, INC $57.91 3
Lilly USA, LLC $57.57 2
ImmunoGen, Inc. $53.50 2
TAIHO ONCOLOGY, INC. $50.90 2
Dendreon Pharmaceuticals LLC $49.20 2
Bayer Healthcare Pharmaceuticals Inc. $41.65 2
Rigel Pharmaceuticals, Inc. $41.55 2
Adaptive Biotechnologies Corporation $39.78 1
Puma Biotechnology, Inc. $33.59 2
Takeda Pharmaceuticals U.S.A., Inc. $29.24 1
Pharmacyclics LLC, An AbbVie Company $29.20 1
Sumitomo Pharma America, Inc. $28.30 1
Pharmacosmos Therapeutics Inc. $26.21 1
MorphoSys, US Inc. $24.77 1
Kyowa Kirin, Inc. $24.67 1
Abbott Laboratories $22.91 1
G1 Therapeutics, Inc. $21.89 1
ARRAY BIOPHARMA INC $21.62 2
ADC Therapeutics America, Inc. $20.86 1
Acrotech Biopharma Inc. $19.69 1
Spectrum Pharmaceuticals Inc. $19.10 1
RECORDATI_RARE_DISEASES_INC. $15.74 1
Stemline Therapeutics Inc. $15.66 1
Janssen Pharmaceuticals, Inc $14.44 1
Alnylam Pharmaceuticals Inc. $14.25 1
Myriad Genetic Laboratories, Inc. $13.92 1

Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VINNI JUNEJA

NPI 1639223522 · CMS profile ID 28412

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALEXANDRIA, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639223522?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VINNI JUNEJA, NPI 1639223522, CMS profile ID 28412. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639223522?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VINNI JUNEJA, NPI 1639223522, CMS profile ID 28412. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639223522?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VINNI JUNEJA, NPI 1639223522, CMS profile ID 28412, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639223522?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

178 matching records · $8,912.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 178 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 178.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $23.7509/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988557453 CMS
Janssen Biotech, Inc. $99.9908/31/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988557459 CMS
Seagen Inc. $18.8008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995801659 CMS
PFIZER INC. $40.2008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050042735 CMS
Seagen Inc. $15.5408/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995801643 CMS
AstraZeneca Pharmaceuticals LP $32.9708/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016230891 CMS
GENZYME CORPORATION $24.6408/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050039805 CMS
Novartis Pharmaceuticals Corporation $18.7208/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992257911 CMS
Celgene Corporation $21.4808/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016011027 CMS
Genentech USA, Inc. $23.9808/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040592637 CMS
Puma Biotechnology, Inc. $15.7908/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059056575 CMS
TAIHO ONCOLOGY, INC. $30.0808/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055228653 CMS
Celgene Corporation $21.7908/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016011041 CMS
PFIZER INC. $21.3408/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049955457 CMS
Seagen Inc. $230.7408/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995801831 CMS
Seagen Inc. $61.5708/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995801841 CMS
Seagen Inc. $61.5708/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995801855 CMS
Kite Pharma, Inc. $25.0508/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270199 CMS
PFIZER INC. $23.5008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049865029 CMS
ABBVIE INC. $18.0708/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997587297 CMS
PharmaEssentia USA Corporation $24.1407/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059316129 CMS
Rigel Pharmaceuticals, Inc. $24.0207/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033414203 CMS
Horizon Therapeutics plc $10.8507/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987026467 CMS
Amgen Inc. $19.3507/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020189793 CMS
Amgen Inc. $22.0607/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020189789 CMS
Horizon Therapeutics plc $11.3707/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987026465 CMS
E.R. Squibb & Sons, L.L.C. $11.2907/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016011019 CMS
Janssen Biotech, Inc. $25.7407/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988557441 CMS
Kite Pharma, Inc. $23.1407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270197 CMS
Amgen Inc. $24.1307/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020189801 CMS
Regeneron Healthcare Solutions, Inc. $26.7907/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999232627 CMS
Horizon Therapeutics plc $26.2607/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987026463 CMS
PFIZER INC. $40.2007/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049306217 CMS
Merck Sharp & Dohme LLC $18.1607/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048773215 CMS
Novartis Pharmaceuticals Corporation $23.5207/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992257907 CMS
Eisai Inc. $22.2006/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023336663 CMS
Horizon Therapeutics plc $28.7606/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987026461 CMS
BeiGene USA, Inc. $30.3906/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051179765 CMS
ImmunoGen, Inc. $24.9906/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017253357 CMS
Astellas Pharma US Inc $21.0906/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034219219 CMS
GlaxoSmithKline, LLC. $24.1406/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001937677 CMS
Spectrum Pharmaceuticals Inc. $19.1006/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059885899 CMS
AVEO Pharmaceuticals, Inc. $24.3606/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049067251 CMS
Kite Pharma, Inc. $21.8506/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270195 CMS
Daiichi Sankyo Inc. $19.0806/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006440461 CMS
RECORDATI_RARE_DISEASES_INC. $15.7406/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060352609 CMS
Mirati Therapeutics, Inc. $37.2906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057994009 CMS
Novartis Pharmaceuticals Corporation $32.2806/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992257903 CMS
E.R. Squibb & Sons, L.L.C. $5.2506/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016010949 CMS
E.R. Squibb & Sons, L.L.C. $0.6506/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016010955 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,307.12 25
PY2020 $3,095.01 83
PY2021 $2,108.40 108
PY2022 $3,410.59 159
PY2023 $8,912.10 178
PY2024 $6,300.65 189
PY2025 $5,678.34 173

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $559,995.59 119
PY2024 Principal investigator $135,901.00 19
PY2023 Principal investigator $25,623.73 4
PY2022 Principal investigator $12,375.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 12/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404513
Principal investigator 1 Janssen Research & Development, LLC $1,599.00 12/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406445
Principal investigator 1 Janssen Research & Development, LLC $22,750.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328670
Principal investigator 1 Janssen Research & Development, LLC $637.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327217
Principal investigator 1 Janssen Research & Development, LLC $3,818.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328265
Principal investigator 1 Janssen Research & Development, LLC $3,818.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328305
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371218
Principal investigator 1 Daiichi Sankyo Inc. $51.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371222
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371224
Principal investigator 1 Daiichi Sankyo Inc. $251.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371228
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371230
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371232
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371238
Principal investigator 1 Daiichi Sankyo Inc. $1,775.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371242
Principal investigator 1 Daiichi Sankyo Inc. $251.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371246
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 12/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371248
Principal investigator 1 ABBVIE INC. $9,612.00 12/04/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202527958
Principal investigator 1 Janssen Research & Development, LLC $9,488.00 12/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405063
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327044
Principal investigator 1 Daiichi Sankyo Inc. $1,874.00 11/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371212
Principal investigator 1 Daiichi Sankyo Inc. $4,047.00 11/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371214
Principal investigator 1 Daiichi Sankyo Inc. $4,047.00 11/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371226
Principal investigator 1 Daiichi Sankyo Inc. $2,012.00 11/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371236
Principal investigator 1 Daiichi Sankyo Inc. $4,047.00 11/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371244
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387551
Principal investigator 1 Daiichi Sankyo Inc. $588.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387553
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404241
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404330
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405235
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406415
Principal investigator 1 Janssen Research & Development, LLC $299.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406943
Principal investigator 1 Janssen Research & Development, LLC $1,599.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407280
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408080
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408619
Principal investigator 1 Janssen Research & Development, LLC $1,599.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408708
Principal investigator 1 Janssen Research & Development, LLC $12,914.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328361
Principal investigator 1 Janssen Research & Development, LLC $4,100.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406081
Principal investigator 1 ABBVIE INC. $7,201.58 11/05/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202522957
Principal investigator 1 Daiichi Sankyo Inc. $2,711.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387533
Principal investigator 1 Daiichi Sankyo Inc. $13,806.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387535
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329465
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175326714
Principal investigator 1 Janssen Research & Development, LLC $494.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175326934
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327051
Principal investigator 1 Janssen Research & Development, LLC $2,596.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328352
Principal investigator 1 Daiichi Sankyo Inc. $1,775.00 10/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371216
Principal investigator 1 Daiichi Sankyo Inc. $500.00 10/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371220
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371234
Principal investigator 1 Daiichi Sankyo Inc. $165.00 10/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371240
Principal investigator 1 Daiichi Sankyo Inc. $295.00 10/14/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387547
Principal investigator 1 ABBVIE INC. $10,067.63 10/09/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514459
Principal investigator 1 Daiichi Sankyo Inc. $236.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387537
Principal investigator 1 Daiichi Sankyo Inc. $2,360.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387539
Principal investigator 1 Daiichi Sankyo Inc. $295.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387541
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387543
Principal investigator 1 Daiichi Sankyo Inc. $295.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387545
Principal investigator 1 Daiichi Sankyo Inc. $295.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387549
Principal investigator 1 Janssen Research & Development, LLC $10,322.00 10/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329333
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 09/29/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406132
Principal investigator 1 Daiichi Sankyo Inc. $90.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387505
Principal investigator 1 Daiichi Sankyo Inc. $295.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387507
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387509
Principal investigator 1 Daiichi Sankyo Inc. $295.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387511
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387513
Principal investigator 1 Daiichi Sankyo Inc. $236.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387515
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387517
Principal investigator 1 Daiichi Sankyo Inc. $82.60 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387519
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387521
Principal investigator 1 Daiichi Sankyo Inc. $295.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387523
Principal investigator 1 Daiichi Sankyo Inc. $236.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387525
Principal investigator 1 Daiichi Sankyo Inc. $90.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387527
Principal investigator 1 Daiichi Sankyo Inc. $1,416.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387529
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387531
Principal investigator 1 Janssen Research & Development, LLC $299.00 09/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405547
Principal investigator 1 Janssen Research & Development, LLC $3,710.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327739
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329295
Principal investigator 1 Janssen Research & Development, LLC $9,242.00 09/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405020
Principal investigator 1 ABBVIE INC. $28,921.73 09/04/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202509310
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387501
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175328922
Principal investigator 1 ABBVIE INC. $27,584.55 08/06/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202503119
Principal investigator 1 Daiichi Sankyo Inc. $12,358.00 08/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387503
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327631
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327652
Principal investigator 1 Janssen Research & Development, LLC $4,200.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175328475
Principal investigator 1 Janssen Research & Development, LLC $8,692.00 07/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407478
Principal investigator 1 ABBVIE INC. $11,850.30 07/02/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202496287
Principal investigator 1 ABBVIE INC. $41,715.68 07/02/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202496299
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/30/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175408956
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 06/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387499
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,100.00 06/10/2025 Non-covered Recipient Entity
Us Oncology
A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therapies. No dispute reported 06/30/2026 1235992265
Principal investigator 1 Janssen Research & Development, LLC $4,100.00 06/09/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406675
Principal investigator 1 ABBVIE INC. $20,478.83 06/03/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202488851
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/27/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371204
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/27/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371206
Principal investigator 1 Janssen Research & Development, LLC $235.00 05/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407072
Principal investigator 1 Janssen Research & Development, LLC $1,599.00 05/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407968
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405056
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,800.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185546273
Principal investigator 1 ABBVIE INC. $15,407.55 05/07/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202484081
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/07/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371208
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/07/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371210
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,750.00 04/30/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185546269
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371202
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $935.00 04/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therapies. No dispute reported 06/30/2026 1235996095
Principal investigator 1 ABBVIE INC. $37,473.10 04/03/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY - SILVER SPRING
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202470022
Principal investigator 1 Janssen Research & Development, LLC $8,692.00 04/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407372
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387495
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387497
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 03/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405195
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 03/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406802
Principal investigator 1 Janssen Research & Development, LLC $4,346.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406104
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 03/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408496
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387217
Principal investigator 1 Janssen Research & Development, LLC $12,836.00 02/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,400.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185546271
Principal investigator 1 Janssen Research & Development, LLC $10,717.00 01/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404828
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, P.a.
DS1062-A-U304 No dispute reported 06/30/2026 1223371200
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $935.00 01/15/2025 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therapies. No dispute reported 06/30/2026 1235996097